Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) EBT (2017 - 2025)

UroGen Pharma (URGN) has disclosed EBT for 9 consecutive years, with -$26.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 23.59% year-over-year to -$26.6 million, compared with a TTM value of -$153.4 million through Dec 2025, down 23.68%, and an annual FY2025 reading of -$153.4 million, down 23.68% over the prior year.
  • EBT was -$26.6 million for Q4 2025 at UroGen Pharma, up from -$34.4 million in the prior quarter.
  • Across five years, EBT topped out at -$21.9 million in Q3 2023 and bottomed at -$48.9 million in Q2 2025.
  • Average EBT over 5 years is -$29.7 million, with a median of -$27.7 million recorded in 2021.
  • The sharpest move saw EBT skyrocketed 32.74% in 2021, then tumbled 57.31% in 2024.
  • Year by year, EBT stood at -$27.3 million in 2021, then dropped by 3.17% to -$28.2 million in 2022, then increased by 21.36% to -$22.2 million in 2023, then plummeted by 57.31% to -$34.9 million in 2024, then grew by 23.59% to -$26.6 million in 2025.
  • Business Quant data shows EBT for URGN at -$26.6 million in Q4 2025, -$34.4 million in Q3 2025, and -$48.9 million in Q2 2025.